Adverum Biotechnologies Announces New Executive Leadership Roles
Retrieved on:
Thursday, May 25, 2023
Gilead Sciences, Adverum Biotechnologies, Drug development, AMD, Pharming, Pharmacovigilance, European Medicines Agency, Lead, Novartis Institute for Tropical Diseases, Biomedical Research, LUNA, PRIME, IVT, Patient, Ophthalmology, Johnson & Johnson, United, Medicines and Healthcare products Regulatory Agency, Pharmaceutical industry, Pittosporum tobira
REDWOOD CITY, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced new executive leadership roles that support the ongoing development of the investigational gene therapy ixoberogene soroparvovec (Ixo-vec). Ixo-vec is currently being evaluated in the Phase 2 LUNA trial as a one-time intravitreal (IVT) injection for patients in the treatment of neovascular or wet age-related macular degeneration (wet AMD).
Key Points:
- Dr. Beckman will continue to advise on Adverum’s pipeline, including Ixo-vec, and support our external engagement with key stakeholders.
- Star Seyedkazemi, Pharm.D., chief development officer, is expanding her responsibilities to lead Adverum’s clinical development, medical affairs and pharmacovigilance teams.
- Dr. Beckman and Dr. Seyedkazemi will continue to report to Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies.
- “I am pleased that he will continue to work with Adverum in his role as senior medical advisor.